TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Distal Radius Buckle Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Children age 1-17 with buckle fractures of the distal radius and/or ulna. -~Exclusion Criteria:~* Patients are excluded if there is any other injury to the upper limb or serious bodily trauma that might complicate pain scores. Children with suspected or proven metabolic bone disease, or pathologic fractures are excluded due to resultant abnormal bone healing.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Supportive Care (Type: EXPERIMENTAL): No casting or splinting, supportive care only by parents
- Cast (Type: ACTIVE_COMPARATOR): Casting for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Pelvic Ring Fractures in the Elderly

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CTI/MRI verified fracture of the sacrum affecting the posterior ring or both posterior and anterior ring~* age\>65 years, ambulatory with/without walking aids before Trauma~* ambulatory with/without walking aids before trauma~* postmenopausal status in women~* informed consent for study participation and surgery~Exclusion Criteria:~* Refusal of consent by the patient or legal representatives to participate in the study~* Other fractures or~* Unstable pelvic fracture (type B or C according to classification of 'Arbeitsgemeinschaft für Osteosynthesefragen' (AO)/OTA) requiring surgical stabilisation after high- or low-energy trauma~* Suspicion of a pathological fracture in the context of known or unknown malignancy~* Previous surgery of the pelvis with metal obstructing the planned paths of the ilio-sacral screws~* Symptomatic low back pain with morphological changes, i.e. intervertebral disc displacement, neoplasm metastasis in the axial skeleton, spinal stenosis, vertebral fracture, spondylarthropathy etc.~* Comorbidity that precludes undergoing general or spinal anaesthesia~* Pre-trauma mobility status that precludes achieving a post-trauma mobility status enabling the patient to perform the timed up and go test (e.g. patient being in a wheel chair)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- experimental intervention surgery (Type: EXPERIMENTAL): screw osteosynthesis of the sacrum and in certain cases additional plate osteosynthesis of dislocated pubic rami fractures, postoperative analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
- control intervention conservative (Type: ACTIVE_COMPARATOR): analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Maytenus Ilicifolia in the Treatment of Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years~* being literate~* diagnosis of dyspepsia~* initial SODA score \> or = 25~Exclusion Criteria:~* pregnancy~* lactation~* allergy to Maytenus species~* fail to use the drug for 3 uninterrupted weeks~* new onset serious adverse events, attributable to the drug~* patient's request

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Maytenus (Type: EXPERIMENTAL): Tea of Martens ilicifolia leaves
- Omeprazole (Type: ACTIVE_COMPARATOR): Omeprazole as active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Karnofsky index \>70%~* Child-Turgotte-Pugh A or B liver score.~* An initial diagnosis of primary HCC or recurrence.~* A technically unresectable lesion or medically contraindicated surgery or a case in which surgery was declined.~* HCC (single nodule ≤ 5 cm or max 3 nodules ≤ 3 cm) diagnosed by histology or non-invasive EASL criteria~* Baseline CT or MRI and bone scan without evidence of radiologically definable major vascular invasion or extrahepatic disease~* Hb \>10.5.0 g/%, WBC \>3.000 cells/mm3, platelets \>50.000 cells/mm3, bilirubin \<2 mg/dl, aspartate and alanine aminotransferase levels \<5 times upper normal limit, and prothrombin time-international normalized ratio ≤ 2;~* Serum creatinine \<1.7 mg/dl~* Previously incomplete TAE or TACE with radiologically defined residual disease.~* Informed consent~Exclusion Criteria:~* Extrahepatic disease and refractory ascites.~* Previous abdominal radiation therapy (RT)~* Hemorrhage/bleeding event = Grade 3 within 4 weeks of enrollment in the study.~* Pregnant or breastfeeding patients.~* Patients with uncontrolled infections or HIV seropositive patients.~* Mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Stereotactic body radiation therapy (Type: EXPERIMENTAL): HCC after incomplete TAE or TACE treated by SBRT
- TACE/TAE (Type: ACTIVE_COMPARATOR): HCC after incomplete TAE or TACE treated by a new cycle of TAE or TACE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Cardioblate CryoFlex Surgical Ablation System in Longstanding Persistent Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a documented history of longstanding persistent AF as defined by the HRS/EHRA/ECAS Guidelines~* Patients should have a concomitant indication (other than AF) for open-heart surgery for mitral valve repair or replacement (bioprosthesis)~* Patients should be older than or equal to 18 years of age~Exclusion Criteria:~* Atrioventricular reentrant tachycardia (AVRT)~* NYHA Class = IV~* Left ejection fraction of ≤ 30%~* Need for emergent cardiac surgery (i.e. cardiogenic shock) or redo open heart surgery~* Previous atrial fibrillation ablation, AV-nodal ablation, or surgical Maze procedure~* Contraindication for anticoagulation therapy~* Left atrial diameter \> 7.0 cm~* Preoperative need for intra-aortic balloon pump or intravenous inotropes~* Renal failure requiring dialysis or hepatic failure~* Life expectancy of less than one year~* Pregnancy or desire to be pregnant within 12 months of the study treatment~* Current diagnosis of active systemic infection~* Documented MI 6 weeks prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardioblate CryoFlex Surgical Ablation (Type: EXPERIMENTAL): Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery. During surgery, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor future episodes of AF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Pacing Stimulus Conduction and Latency Measurements in CRT-D Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has been implanted with a CRT-D device by BIOTRONIK at least 4 weeks before enrollment date~* Patient successfully implanted with a left ventricular lead~* High likelihood of LV latency ≥ 40 ms~* LV lead in lateral or postero-lateral position in the coronary venous system~* Patient is able to understand the nature of the clinical investigation~* Patient is willing to undergo the required measurements at the investigation site~* Patient provides written informed consent~* Age ≥ 18 years~Exclusion Criteria:~* Patients with irregular ventricular rhythm due to atrial tachycardia~* Pregnant or breast-feeding women~* Participation in an interventional clinical investigation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT-D Measurements (Type: OTHER): Pre-specified measurements and additional follow-ups

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant presents with at least 3 episodes of non-bilious, non-bloody vomiting within the 24 hours prior to visiting the physician's office. The participant has at least 2 signs and symptoms other than vomiting consistent with acute gastroenteritis (AG) (example, fever, nausea, diarrhea, abdominal pain, bloating, or discomfort) within 3 hours prior to visiting the physician's office~* The participant has mild-to-moderate dehydration~* The participant had at least 1 episode of non-bloody diarrhea within the 24 hours prior to the visiting the physician's office~Exclusion Criteria:~* The participant has severe dehydration or severe malnutrition~* The participant who has vomiting and clinical symptoms for longer than 72 hours prior to the baseline physician's office visit~* The participant needs intravenous (IV) fluid replacement~* The participant has chronic severe diarrhea, a previous history of Helicobacter pylori infection or received treatment for H. pylori-induced gastritis, active peptic ulcer, celiac disease, Crohn's disease, ulcerative colitis, eosinophilic esophagitis, malabsorption, short bowel syndrome, post-viral gastroparesis, cyclic vomiting syndrome, or previous gastrointestinal surgery~* The participant has upper respiratory symptoms such as cough, congestion, otitis media or pharyngitis

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Oral Rehydration Therapy (ORT) + Domperidone (Type: EXPERIMENTAL): Each participants will initiate ORT in the physician's office and domperidone 0.25 milligram per kilogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
- Oral Rehydration Therapy + Placebo (Type: EXPERIMENTAL): Each participants will initiate ORT in the physician's office and placebo oral suspension thrice daily for up to 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with LBD who completed a previous nelotanserin VH or RBD study~Exclusion Criteria:~* Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid, gastrointestinal, renal, hematologic or other medical disorder

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nelotanserin (Type: EXPERIMENTAL): Once Daily, Oral, at 20, 40, 60, or 80 mg dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: INNO-105 in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Have a histologically or cytologically confirmed diagnosis of a solid malignancy (patients may have either measurable or nonmeasurable disease).~2. Be ≥18 years old.~3. Not eligible for effective therapy likely to provide clinical benefit.~4. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.~5. Acceptable pretreatment clinical laboratory results.~6. Life expectancy of greater than 12 weeks.~Exclusion Criteria:~1. Have received previous treatment with INNO-105.~2. Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.~3. Are pregnant or lactating.~4. Have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.~5. Have received any chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational, within 2 weeks of treatment in this study.~6. Have not recovered from acute toxicity of all previous therapy prior to enrollment.~7. Have symptomatic or untreated central nervous system (CNS) metastases.~8. Have a susceptibility to hypotension, bradycardia, and/or hypopnea, such as patients with known coronary heart disease, arrhythmias, cerebral vascular disease, and chronic obstructive airways disease (CO2-retaining).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \>18 y of age;~2. acute onset of focal neurological deficit consistent with acute ischemic stroke;~3. measurable neurological deficit (NIHSS ≥ 5);~4. anterior-circulation ischemic stroke defined by magnetic resonance angiography (MRA) and Diffusion-Weighted Imaging(DWI);~5. onset of symptom to admission more than 4.5 h and less than 72 h. Patients who arrived within 0-4.5 h poststroke were treated with other medications according to the best accepted medical treatment guidelines.~Exclusion Criteria:~1. Other diseases of the central nervous system~2. There has been neurological disability in the past (mRS score\>2)~3. Difficulty swallowing~4. Arrhythmia, atrioventricular block~5. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs~6. Macular edema~7. MRA shows vertebral basilar artery obstruction~8. Hemorrhagic stroke~9. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product~10. Pregnant and lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard management plus Dimethyl Fumarate (Type: EXPERIMENTAL): None
- standard management (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Implants and Locators for Improved Retention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 45-80 years (male or female)~* sufficient full dentures in the mandible~* must be able to clean their teeth on their own~* edentulous mandible with interforaminal adequate bone for insertion of implants~* implantation sites free of infections and root fragments~* no need for treatment of the maxillary teeth~* Written Informed Consent~Exclusion Criteria:~* systemic diseases~* mental disability that may affect the participant's ability to properly follow study instructions~* oral mucosal diseases~* long-term medication with steroids, bisphosphonates~* known allergic reactions to dental materials~* malignant tumor in the head and neck area~* requirement of any concurrent radiotherapy or chemotherapy or any radiotherapy or chemotherapy within the last 10 years pregnancy or breastfeeding at study entry

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A Locator with retention elements (Type: EXPERIMENTAL): GC Pilier Locator abutment with retention elements:~For patients in the experimental group (arm A) the connection of the full dentures to the implants will be achieved by fitting the dentures with GC Pilier Locator abutments with retention elements.
- B Locator without retention elements (Type: ACTIVE_COMPARATOR): GC Pilier Locator abutment without retention elements:~For patients with the active comparator (arm B) the full dentures will get Pilier Locator abutments without retention elements and thus no connection to the implants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Shilla Growth Permitting Spinal Instrumentation System for Treatment of Scoliosis in the Immature Spine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* between the ages of 1 yr and 10 yrs~* have severe, progressive scoliosis unresponsive to bracing~* have severe, progressive scoliosis who cannot tolerate bracing~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- 1 Shilla Technique (Type: None): The patients whose data is observed are those who have undergone the shilla surgical technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid tumors that have failed auto transplant or are ineligible to receive auto transplant~* Relapsed AML in 1st relapse or 2nd or 3rd CR~* Relapsed ALL if they fail to attain an initial remission or if they relapse within 1 year following the discontinuation of chemotherapy.~* Greater than or equal to 6 months and \<26 years old~* Suitable haploidentical donor available~Exclusion Criteria:~* Leukemia with \>25% blasts in bone marrow at the time of admission to the HSCT unit.~* Serum bilirubin \>3 mg/dl~* GFR \<40 ml/min/1.73 mw~* Cardiac left ventricular ejection fraction \<40%~* HIV+~* Pregnant

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues